Skip to main content

Drug Interactions between Ellence and margetuximab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

epiRUBicin margetuximab

Applies to: Ellence (epirubicin) and margetuximab

GENERALLY AVOID: Coadministration of margetuximab and anthracyclines may increase the risk of cardiac dysfunction. Margetuximab and anthracyclines are individually cardiotoxic and may have additive effects during coadministration. Four months after discontinuation, margetuximab concentrations decreased to approximately 3% of its steady-state trough serum concentration. Therefore, use of anthracyclines within 4 months after stopping margetuximab may also carry a higher risk of cardiac dysfunction.

MANAGEMENT: Anthracycline-based therapy should be avoided during and for up to 4 months after stopping use of margetuximab. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.

References

  1. (2021) "Product Information. Margenza (margetuximab)." Almirall

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer